CYDY Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to CytoDyn, Inc.'s net margin of 16.99%. CytoDyn, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

CytoDyn, Inc. has a consensus price target of --, signalling upside risk potential of 1442.38%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that CytoDyn, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe CytoDyn, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

CytoDyn, Inc. has a beta of 1.130, which suggesting that the stock is 12.988% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

CytoDyn, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoDyn, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

CytoDyn, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. CytoDyn, Inc.'s net income of -$22.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, CytoDyn, Inc.'s price-to-earnings ratio is 121.23x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoDyn, Inc. is -- versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -- compared to CytoDyn, Inc.'s net margin of -3.91%. CytoDyn, Inc.'s return on equity of -- beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.

CytoDyn, Inc. has a consensus price target of --, signalling upside risk potential of 1442.38%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 38.69%. Given that CytoDyn, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe CytoDyn, Inc. is more attractive than BioMarin Pharmaceutical, Inc..

CytoDyn, Inc. has a beta of 1.130, which suggesting that the stock is 12.988% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

CytoDyn, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoDyn, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

CytoDyn, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. CytoDyn, Inc.'s net income of -$22.6M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, CytoDyn, Inc.'s price-to-earnings ratio is 121.23x while BioMarin Pharmaceutical, Inc.'s PE ratio is 24.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoDyn, Inc. is -- versus 4.06x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Imunon, Inc. has a net margin of -- compared to CytoDyn, Inc.'s net margin of --. CytoDyn, Inc.'s return on equity of -- beat Imunon, Inc.'s return on equity of -365%.

CytoDyn, Inc. has a consensus price target of --, signalling upside risk potential of 1442.38%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 567.7%. Given that CytoDyn, Inc. has higher upside potential than Imunon, Inc., analysts believe CytoDyn, Inc. is more attractive than Imunon, Inc..

CytoDyn, Inc. has a beta of 1.130, which suggesting that the stock is 12.988% more volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.

CytoDyn, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoDyn, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.

CytoDyn, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. CytoDyn, Inc.'s net income of -$22.6M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, CytoDyn, Inc.'s price-to-earnings ratio is 121.23x while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoDyn, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -- compared to CytoDyn, Inc.'s net margin of --. CytoDyn, Inc.'s return on equity of -- beat Savara, Inc.'s return on equity of -78.83%.

CytoDyn, Inc. has a consensus price target of --, signalling upside risk potential of 1442.38%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that CytoDyn, Inc. has higher upside potential than Savara, Inc., analysts believe CytoDyn, Inc. is more attractive than Savara, Inc..

CytoDyn, Inc. has a beta of 1.130, which suggesting that the stock is 12.988% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

CytoDyn, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoDyn, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

CytoDyn, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. CytoDyn, Inc.'s net income of -$22.6M is higher than Savara, Inc.'s net income of -$29.6M. Notably, CytoDyn, Inc.'s price-to-earnings ratio is 121.23x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoDyn, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.